Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Azitra Taps Microbiome For Dermatology Therapies, Including Cancer Supportive Care

Executive Summary

Emerging Company Profile: Based on its founders’ research at Yale, Azitra is developing topical therapies to treat skin dysbiosis associated with chemotherapy as well as two approaches to atopic dermatitis.

You may also be interested in...



Bayer Harnessing Skin Microbiome In New Product Development

Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions. 

Finance Watch: BIO Says Proposed Foreign Investment Regulations Will Lower Investment In US Biotech

Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.

Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas

Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL043097

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel